Unicycive Therapeutics Inc（UNCY）股票分析

AI 分析 of Unicycive Therapeutics Inc (UNCY)

持有

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.

估值指標

Unicycive Therapeutics Inc（UNCY）目前預期本益比為 1.99，5 年平均預期本益比為 0.45。

預期本益比

合理

5 年均值 P/E

0.45

目前P/E

1.99

高估

7.03

低估

-6.13

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-6545.04

目前EV/EBITDA

0.00

高估

23017.88

低估

-36107.96

預期股價營收比

合理

5 年均值 P/S

4.06

目前P/S

0.74

高估

15.58

低估

-7.46

Alphio AI 對 UNCY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%UNCY

$5.26

情境價格

基

基準

基準 · 50%UNCY

$4.33

情境價格

悲

悲觀

悲觀 · 25%UNCY

$3.97

情境價格

持有 UNCY 的大戶

L

Logos Global Management, L.P.

+ 持有UNCY

+20.59%

3個月報酬率

UNCY 常見問題 —— 由 Alphio AI 解答

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Unicycive Therapeutics Inc is currently not a strong buy due to its recent performance and technical indicators. The current price is $3.49, which is significantly below its 52-week high of $8.74, indicating a potential for recovery but also substantial risk. The RSI is at 32.171, suggesting the stock is oversold, but the recent 5-day change is -2.51%, reflecting continued downward pressure. The forward P/E ratio is 2.0661, which could indicate potential value, but the company has a negative net income and gross profit in recent quarters, with a net income of -21,525,000 USD in Q4 2024 and -6,447,000 USD in Q2 2025. The main risk is the ongoing FDA issues, as highlighted by the recent news of executives being sued for failing to ensure compliance, which could further impact stock performance.